Arrowhead drug cuts tau levels 73% in early trial data
Tweet Send to a Friend
Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported interim Phase 1/2a clinical data for ARO-MAPT, its investigational RNA interference (RNAi) therapy targeting tau ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




